Drug intelligence / Profile preview

PF-3644022

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules

Overview

PF-3644022 is a small molecule inhibitor of mitogen-activated protein kinase 2 (MAPKAPK2 or MK2), a downstream effector in the p38 MAPK signaling pathway. It is designed to modulate inflammatory responses by inhibiting MK2 activity. The compound has been studied for its pharmacological properties and potential as an anti-inflammatory agent in preclinical models. Its molecular formula is C21H18N4OS and it has been characterized structurally and biochemically as an experimental drug candidate[1][5][7].

Other names: DB07430DB-07430DB 07430

Targets

MK2 (Mitogen-activated protein kinase-activated protein kinase 2)

Beyond the preview

Go deeper on PF-3644022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-3644022.

Explore the full profile